Rockwell Medical Announces Acquisition of Generic Drug Vitamin-D to Treat Secondary Hyperparathyroidism in ESRD Patients

Rockwell Medical RMTI announced today that it has acquired an Abbreviated New Drug Application for injectable, active Vitamin-D (Calcitriol) for End Stage Renal Disease patients undergoing hemodialysis. Terms were not disclosed. Mr. Robert L. Chioini, Chairman and CEO of Rockwell Medical stated that, "We are excited to add another renal drug to our expanding pipeline of products. The new bundled-reimbursement for hemodialysis has provided us an ideal opportunity to leverage our existing operating business with more profitable renal products, and we expect this drug, coupled with our current distribution model, will enable us to penetrate the Vitamin-D market effectively. We view this new drug as incrementally positive and accretive in mid-2012."